Literature DB >> 2536801

Peripheral neuropathies during treatment with almitrine: report of 46 cases.

P Bouche1, L Lacomblez, J M Leger, M P Chaunu, H Ratinahirana, P Brunet, J J Hauw, H P Cathala, D Laplane.   

Abstract

Almitrine bismesylate is thought to cause sensory peripheral neuropathy. Forty-six patients are reported who received almitrine bismesylate alone for chronic respiratory failure or in combination with raubasine for various cerebrovascular diseases. Polyneuropathy appeared between 9 and 25 months after the onset of treatment. Sensory signs and symptoms were confined to the distal parts of the lower limbs and involved large and small fibres. Histological and electrophysiological findings indicated axonal degeneration. Respiratory failure could have caused the polyneuropathy in some cases but many had no chest disease. Patients began to improve between 3 and 6 months after withdrawal of the drug. Recovery was usually complete after 12 months.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536801     DOI: 10.1007/bf00314214

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Peripheral neuropathy in chronic disease of the respiratory tract.

Authors:  O Appenzeller; R D Parks; J MacGee
Journal:  Am J Med       Date:  1968-06       Impact factor: 4.965

2.  Almitrine and peripheral neuropathy.

Authors:  S M Alani; J A Twomey; M D Peake
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

3.  Peripheral neuropathy in chronic obstructive lung disease.

Authors:  N Moore; G Lerebours; J Senant; G Ozenne; P David; G Nouvet
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

4.  Evidence of motor neuron involvement in chronic respiratory insufficiency.

Authors:  G Valli; S Barbieri; P Sergi; Z Fayoumi; P Berardinelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

5.  Nerve conduction impairment in patients with respiratory insufficiency and severe chronic hypoxemia.

Authors:  M Narayan; R Ferranti
Journal:  Arch Phys Med Rehabil       Date:  1978-04       Impact factor: 3.966

6.  Almitrine neuropathy. A nerve biopsy study of 8 cases.

Authors:  R Gherardi; M Baudrimont; F Gray; F Louarn
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  [Peripheral neuropathy during treatment with cimetidine].

Authors:  J Pouget; J F Pellissier; P Jean; J Jouglard; M Toga; G Serratrice
Journal:  Rev Neurol (Paris)       Date:  1986       Impact factor: 2.607

8.  [Incidence of polyneuropathies in chronic obstructive bronchopneumopathies].

Authors:  B Paramelle; A Vila; P Pollak; P Muller; D Gavelle; F Reymond; C Brambilla; P Stoebner
Journal:  Presse Med       Date:  1986-03-22       Impact factor: 1.228

9.  [Sensorimotor polyneuropathy induced by almitrine dimesylate. Anatomo-clinical study of a case].

Authors:  J J Rousseau; C A Lust; J M Brucher
Journal:  Acta Neurol Belg       Date:  1987 Aug-Oct       Impact factor: 2.396

10.  [Painful legs and unstable toes].

Authors:  J M Léger; C Lubetzki; P Bouche; Y Bor; P Brunet
Journal:  Rev Neurol (Paris)       Date:  1985       Impact factor: 2.607

View more
  3 in total

1.  Almitrine-induced peripheral neuropathy and weight loss.

Authors:  R Gherardi; L Bélec; F Louarn
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

2.  Lipidosis of the dorsal root ganglia in rats treated with an almitrine metabolite.

Authors:  Y Yamanaka; E Sakamoto; Y Sakuma; H Uno; T Koyama; Y Izawa; K Fujiwara
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

3.  Pharmacological interventions in acute respiratory distress syndrome.

Authors:  Antoine Roch; Sami Hraiech; Stéphanie Dizier; Laurent Papazian
Journal:  Ann Intensive Care       Date:  2013-07-03       Impact factor: 6.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.